The Obesity Drug Landscape
How retatrutide compares to approved drugs, pipeline competitors, and the regulatory path ahead
The Competitive Field
Retatrutide enters the most crowded and competitive drug landscape in decades. Semaglutide dominates the market, tirzepatide is gaining ground fast, and a wave of next-generation compounds are in late-stage trials. This unit maps the entire field -- approved drugs, pipeline candidates, oral formulations, and combination therapies -- so you can understand exactly where retatrutide fits and why Eli Lilly is betting on triple agonism as the next leap forward.
vs Semaglutide
Head-to-head comparison: mechanisms, weight loss, side effects, and market position.
vs Tirzepatide
Dual vs triple agonism: what the glucagon receptor adds to the equation.
Pipeline Drugs
Survodutide, CagriSema, orforglipron, amycretin, and other emerging therapies.
Regulatory Timeline
Phase 3 completion estimates, FDA filing timeline, and expected approval date.
Choosing a Therapy
Framework for understanding which drug class fits which patient profile.